AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02096094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bath with chlorhexidine
Description: Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
Study NCT00909155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine ERT
Description: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
Study NCT00909155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
Study NCT03955094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation via AMBU® AURAGAIN™
Description: Success rate of paediatric intubation through AMBU® AURAGAIN™
Study NCT02920060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam
Description: intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
Study NCT02920060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
Study NCT02382094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT02382094 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bicalutamide
Study NCT03436173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 10 mg/2.5 ml mixed with water
Study NCT03436173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peppermint syrup
Description: Liquid peppermint syrup measured to the equivalent volume and mixed with water
Study NCT00938730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00938730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: oral
Study NCT03359902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
Study NCT03359902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes placed on earlobe
Study NCT02964598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified intervention
Description: A new mobile application for assisting in sleep regulation, duration 4-6 weeks
Study NCT02964598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep coaching
Description: A new personalized program, duration 4-6 weeks
Study NCT02964598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Morning bright light 10 000 lux maximum duration 4-6 weeks
Study NCT02964598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Minimal information on sleep timing and advancing the sleep rhythm
Study NCT02964598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: An extensive information platform in the internet created for this purpose
Study NCT01852084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista® One-Piece Hydrophobic Acrylic Toric IOL
Description: Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
Study NCT01852084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista control lens
Description: Spherical Control lens
Study NCT00578357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized feedback intervention
Description: personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Kinesio Taping
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Kinesio Taping
Study NCT01886768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double pledget nasal anesthesia (DPNA)
Description: By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
Study NCT01886768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single pledget nasal anesthesia (SPNA)
Description: Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
Study NCT02158182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
Study NCT02158182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: 10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
Study NCT02158182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 2 tablets (400mg) three times daily. Duration of therapy: 7 days
Study NCT02158182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.
Study NCT04725708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: procedure: cerebral oxygenation intervention
Description: During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
Study NCT01364805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Description: The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
Study NCT01364805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
Study NCT03659006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological Collection
Description: Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
Study NCT00413764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tibolone
Description: tibolone (2.5 mg) over 24 weeks
Study NCT00413764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol-norethisterone
Description: transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Study NCT03550625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computer program
Description: No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
Study NCT01861262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of StO2
Description: The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
Study NCT02516657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide 0.6 mg
Study NCT01723748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genotropin
Description: iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
Study NCT04901156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1Hz inhibitory rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
Study NCT03478397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent mHealth Intervention
Description: Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
Study NCT00423787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed MATA MPL
Description: 4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml
Study NCT02216812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin c, 1 pill per day for 6 weeks
Study NCT02216812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 placebo pill for 6 weeks
Study NCT03470727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Description: Change form acetate to citrate dialysate
Study NCT03610529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioSenseSystem
Description: CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
Study NCT03610529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Intellivue
Description: Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
Study NCT03387488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StingrayTM, Medtronic®
Description: Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
Study NCT02337231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil and borage oil
Description: Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
Study NCT01659879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia information
Study NCT04826653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture removal
Description: Suture removal after coronally advanced flap plus a connective tissue graft
Study NCT04901156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study NCT04901156 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study NCT00724477 — intervention group
Intervention type: DRUG
Intervention: INEGY
Description: Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
Study NCT04901156 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1Hz sham rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
Study NCT02139956 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: open
Study NCT02567448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and pulmonary physiologic measurements
Description: Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
Study NCT00005724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Program Intervention Group
Description: A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
Study NCT00005724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Intervention Group
Description: Dietary Information pamphlets.
Study NCT01659879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: verbal information
Study NCT02667353 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ECT
Description: ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
Study NCT02667353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etomidate
Description: Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
Study NCT02667353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
Study NCT00649597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting
Study NCT00005724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Counselor Intervention Group
Description: Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
Study NCT04324645 — intervention group
Intervention type: OTHER
Intervention: Noona Software
Description: Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
Study NCT03844867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Filippo Cea and Carmel
Description: Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds).
Study NCT00961961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium / Fluoxetine
Description: Individualized Daily Dosage
Study NCT00961961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium / Fluoxetine
Description: Individualized Daily Dosage
Study NCT00961961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium / Placebo
Description: Individualized Daily Dosage
Study NCT00961961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium / Placebo
Description: Individualized Daily Dosage
Study NCT03666351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine 5 mg
Study NCT03666351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan Potassium 50 mg
Study NCT03680222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reversed Tracking Method
Description: Reversed Tracking Method
Study NCT03002077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for IV injections.
Study NCT03086473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine Citrate
Description: The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
Study NCT03086473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (Normal Saline)
Description: The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
Study NCT03122457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination
Description: At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
Study NCT01273805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study NCT02480322 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)
Study NCT03115242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast injection Sonovue®
Description: In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
Study NCT02465697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reappraisal Training
Study NCT03666351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan and Amlodipine
Description: Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
Study NCT03666351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Losartan/Chlorthalidone
Description: Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
Study NCT03666351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: current treatment
Description: treatment is done by maintaining the current treatment
Study NCT03303989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 MG/ML [Krystexxa]
Description: Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.